Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: TherapeuticsMD Inc (TXMD)

TherapeuticsMD Inc (TXMD) - corporate logo

The current quotes for TherapeuticsMD, Inc. (TXMD) displayed on the GURU.Markets platform show an EV/EBITDA of 0.00. Sales stability is driven by female consumer loyalty to proven hormonal product lines. The company achieves broad audience reach by developing products for various life stages, including menopause. Financial stability is supported by a lack of debt, although revenue relies on licensing royalties and patent protection.

TXMD TherapeuticsMD: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/14/2026

therapeuticsmd.com - analytical breakdowns and key metrics (TXMD)

- stock price and consensus target price:
Stock Quotes TherapeuticsMD|TXMD - Consensus Target
- company stock exchange capitalization indicators:
Market Value TXMD|TXMD - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share TherapeuticsMD|TXMD - Company Net Assets|Market Capitalization to Book Value Ratio therapeuticsmd.com|TXMD - Company Assets
- debt and liquidity data:
Debt to Equity TherapeuticsMD, Inc.|TXMD - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio TherapeuticsMD|TXMD - Company Cumulative Indebtedness|Debts to Book Capitalization TXMD|TXMD - Company Long-Term Loans and Borrowings|Company Short-Term Debts TherapeuticsMD|Quick Liquidity therapeuticsmd.com
- business earnings and investment ratios data:
TXMD - Final Profit|Projected Future Earnings TherapeuticsMD, Inc.|TXMD - P/E Multiple|Future Price to Earnings TherapeuticsMD|TXMD - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple TXMD|TXMD - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months TherapeuticsMD|TXMD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months therapeuticsmd.com|TXMD - Net earnings per one share growth for the current year|Earnings growth forecast for next year TherapeuticsMD, Inc.
- sales and revenue data:
TXMD - Company Gross Revenue|Projected Sales Volume TherapeuticsMD|TXMD - Market Cap to Revenue|Price-to-Projected Revenue Ratio TXMD
General company analysis:TherapeuticsMD Corp TXMD
Original product of TherapeuticsMD Inc

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest, allowing for an asset valuation independent of capital structure. By analyzing the change in the EV/EBITDA value over time, a TherapeuticsMD, Inc. (TXMD) investor can determine a fair share price, given that the diversification of women's health medications and licensing contracts stabilize the company's cash flows.

Key competitors

Organon Corp - Enterprise Value to EBITDA Ratio|DARE - Enterprise Value to EBITDA Ratio|PTN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization